Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Het effect van de vitamine B12 toediengsvorm op het verloop van de hoeveelheid vitamine B12 in het bloed.

- candidate number10198
- NTR NumberNTR3005
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR27-jul-2011
- Secondary IDsNL33450.029.11 / 2011-001542-15; CCMO / EudraCT
- Public TitleHet effect van de vitamine B12 toediengsvorm op het verloop van de hoeveelheid vitamine B12 in het bloed.
- Scientific TitleEffect of administration route on the pharmacokinetics of cobalamin in elderly.
- ACRONYMnot applicable
- hypothesisIntranasal administration of cobalamin can be used as an alternative for the standard intramuscular injection of cobalamin in cobalamin deficient patients.
- Healt Condition(s) or Problem(s) studiedVitamin B12 deficiency, Older adults
- Inclusion criteria1. Cobalamin deficiency i.e. cobalamin level less than 200 pmol/l;
2. 65 years of age or over;
3. Capable of understanding the study information;
4. Informed consent.
- Exclusion criteria1. Concomitant use of nasally administered medication;
2. Chronic Rhinitis;
3. Running nose;
4. Clinical relevant infection;
5. Hemodynamic instability;
6. Short Nutritional Assessment Questionnaire (SNAQ) score of 3 or over;
7. Use of cobalamin containing dietary supplements;
8. Severe Renal impairment i.e. MDRD less than 20 ml/min;
9. Ethical or medical reasons upon discretion of the investigators.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 27-jul-2011
- planned closingdate30-nov-2011
- Target number of participants10
- Interventions1. 5 subjects will receive 1 dose of 1000 mcg cobalamin administered by intramuscular injection;
2. 5 subjects will reveive 1 dose of 1000 mcg cobalamin administered by intranasal spray.
- Primary outcomeArea Under the Curve (AUC) at 48 hours.
- Secondary outcome1. Time to maximum concentration (Tmax);
2. Maximum concentration (Cmax);
3. Elimination half life (T1/2).
- TimepointsBlood samples will be drawn at t = 0, 15, 30, 45, 60, 120, 240, 480, 1440, 2880 minutes.
- Trial web siteN/A
- statusopen: patient inclusion
- Sponsor/Initiator Stichting Apotheek der Haarlemse Ziekenhuizen (SAHZ)
- Funding
(Source(s) of Monetary or Material Support)
Stichting Apotheek der Haarlemse Ziekenhuizen (SAHZ)
- PublicationsN/A
- Brief summaryBackground of the study:
Approximately 10-15% of the population aged 65 years and older has cobalamin (Vitamin B12) deficiency. An even higher prevalence of 30-40% is reported for malnourished and sick elderly people. Cobalamin serves as a cofactor for several vital biochemical reactions. If deficient, people may suffer from anaemia, irreversible neurological damage resulting in cognitive impairment, and neuropsychiatric disorders. Cobalamin deficiency is due to malabsorption of food-bound cobalamin or insufficient dietary intake. Administration of cobalamin by way of intramuscular injection is the gold standard for cobalamin deficiency treatment. It, however, has several disadvantages. Injections are painful, injection related adverse reactions may occur, and health care professionals are usually needed to administer these injections. The latter increases the costs of the treatment considerably. A more convenient, safer and cost-effective treatment would, therefore, be advantageous to both patients and the health care system in general. Food-bound cobalamin is actively absorbed. In contrast, crystalline cyanocobalamin administered in capsules is absorbed by way of passive diffusion although at a relatively low efficiency. Approximately 1% of an oral dose of crystalline cyanocobalamin is absorbed. Oral administration of cyanocobalamin is, however, efficacious in normalising serum cobalamin levels. Oral treatment is not an option in patients that are unable to take oral medication or patients with severe diarrhoea or vomiting. Dysphagia is a common condition in the elderly population due to age related pathologic changes or due to cerebrovascular diseases affecting the swallowing mechanism. Intranasal administration of cobalamin seems a suitable alternative for both cobalamin injections and oral administration in elderly. The absorption of intranasal administered cobalamin was demonstrated in two studies. In these studies, intranasal administration of cobalamin has not been compared to intramuscular administered cobalamin. Insight in the pharmacokinetics of intranasal administered cobalamin in comparison with intramuscular injection is, however, required to determine the optimal dosage regimen. In addition, the absorption of intranasal administered cobalamin has been examined in healthy elderly volunteers and patients with ileal resections or Crohn’s disease only, though cobalamin deficiency is more prevalent in the sick and/or malnourished elderly population. In order to determine a dosage regimen for intranasal administered cobalamin in elderly patients insight in the pharmacokinetics of intranasal administration compared to intramuscular administration of cobalamin has to be obtained. Because there are no published pharmacokinetic data of intramuscular cobalamin in elderly patients both routes of administration need to be investigated. In this study we investigate the effects of two routes of administration i.e. cobalamin administered intranasally and cobalamin administered by intramuscular injection on the pharmacokinetics as expressed in the standard parameters AUC48hours, Cmax, Tmax and T1/2 in eldery patients.
- Main changes (audit trail)
- RECORD27-jul-2011 - 15-sep-2011

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar